Navigation Links
Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial

CAMBRIDGE, Mass., May 14 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) today announced that the results from its Phase II coronary revascularization trial have been published in the peer-reviewed EuroIntervention Journal. The paper is entitled "Proof-of-concept trial to evaluate haemoglobin based oxygen therapeutics in elective percutaneous coronary revascularization. Rationale, protocol design, and haemodynamic results." The manuscript was authored by principal investigator Patrick W. Serruys, MD, PhD and colleagues of the Department of Interventional Cardiology, Thoraxcenter, Erasmus MC, University Medical Centre Rotterdam, The Netherlands.

"Biopure's COR-0002 study in the EuroIntervention Journal demonstrates the potential use of Hemopure (HBOC-201) in patients with coronary artery disease," said Biopure Chairman and CEO Zafiris G. Zafirelis. "Based on the efficacy and safety of the drug in this trial, we believe that Hemopure could be an oxygen bridge to prevent permanent myocardial damage in patients sustaining a heart attack."

The COR-0002 trial is a single-blind, open-label, single-center, cross- over pilot study where subjects underwent coronary balloon occlusion, with and without oxygenated HBOC-201. The primary objective of the study was to test the hypothesis that intracoronary infusion of HBOC-201 during brief, total coronary artery occlusion would preserve left ventricular function. The primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment changes as assessed via electrocardiograms.

The study concluded that HBOC-201 was indeed capable of preserving left ventricular function, likely through maintenance of myocardial oxygenation. According to the findings, the absence of coronary vasoconstriction, despite exposure to undiluted HBOC-201, further supports the potential utility of HBOC-201 in complicated patient subsets such as those with coronary artery disease. In addition, changes in electrocardiograms, indicating severe ischaemia during control coronary artery occlusions, were not present during or following HBOC-201 infusion. The report states that HBOC-201 did not cause any serious adverse event or significantly alter blood chemistry parameters through the 4-day follow-up period.

Based on the results, the authors hypothesized that, in an acute setting, HBOC-201 could serve as an oxygen bridge to reperfusion by percutaneous coronary intervention, extending the "golden" time period during which permanent myocardial damage is unlikely. The report noted that further studies will be required to determine whether HBOC-201 can enhance treatment efficacy in more complicated patient populations. The report concluded that this trial represents an important next step in the clinical development program for this product as a treatment for acute myocardial ischaemia.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government- funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch in 1998.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Biopure Reports on Meeting with the FDA
2. Biopure Announces 2007 Third Quarter Financial Results
3. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
4. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
5. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
6. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
7. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
8. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
9. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
10. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... The temporary closing of Bruton Memorial Library on June 21 due to a possible lice ... overlooked aspect of head lice: the parasite’s ability to live away from a human host, ... a necessary one in the event that lice have simply gotten out of control. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):